According to available data on cBioPortal, mutation of EZH2 is uncommon in AML cell lines, with a single cell line identified as harboring a Y646C predicted gain-of-function mutation (SKM-1) (Palau et al., 2017) and three cell lines harboring predicted loss-of-function mutations: PL-21 (Quentmeier et al., 2003), OCI-AML5 (Wang et al., 1991), and P31/FUJ (Hirose et al., 1982). This evidence concerns the gene EZH2 and acute myeloid leukemia.